Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today ...
Biodexa Pharmaceuticals PLC has announced a change in its American Depositary Receipts (ADR) ratio, effective July 31, 2025. The new ratio will be one ADR representing 100,000 ordinary shares, up from ...
First Phosphate Corp. (CSE: PHOS) (OTCQX: FRSPF) (OTCQX ADR: FPHOY) (FSE: KD0) ("First Phosphate" or the "Company") is pleased to announce the launch of its sponsored Level 1 American Depositary ...
Zacks Investment Research on MSN
Miniso Group Holding Limited unsponsored ADR (MNSO) declines more than market: Some information for investors
MINISO Group Holding Limited Unsponsored ADR (MNSO) ended the recent trading session at $18.19, demonstrating a -5.99% change from the preceding day's closing price. The stock's performance was behind ...
Zacks Investment Research on MSN
PDD Holdings Inc. sponsored ADR (PDD) surpasses market returns: Some facts worth knowing
PDD Holdings Inc. Sponsored ADR (PDD) closed at $106.88 in the latest trading session, marking a +1.06% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.77% for ...
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet ...
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain, announces a ratio change ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results